Daniel G Welch
CIK 1206199 · Chairman, CEO and President · last filed 2026-06-18
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
SGEN price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
4 UNIVERSITY PLACE
DURHAM, NC 27707
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| GPCR | Director | 123,508 | $21.39 | $2.64M | $0 | 5 | 2026-06-18 |
| RARE | Director | 40,441 | $16.40 | $663.2K | $0 | 13 | 2026-05-18 |
| PRTA | Director | — | $8.51 | — | $0 | 4 | 2026-05-15 |
| Nuvation Bio Inc. (NUVB.WS) Delisted | Director | 659,947 | $0.01 | $3.4K | $0 | 6 | 2024-05-29 |
| Seagen Inc. (SGEN) Delisted | Director | 0 | $228.74 | $0 | -$34.84M | 31 | 2023-12-15 |
| INTERCEPT PHARMACEUTICALS, INC. (ICPT) Delisted | Director | 8,060 | $19.00 | $153.1K | -$102.1K | 8 | 2020-06-01 |
| AveXis, Inc. (AVXS) Delisted | Director | 0 | — | — | $0 | 4 | 2018-05-15 |
| HYPERION THERAPEUTICS INC (HPTX) Delisted | Director | 0 | — | — | $0 | 3 | 2015-05-08 |
Recent Filings · Page 10 of 12
118 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2012-07-31 | Seagen Inc. (SGEN) Delisted | Exer (M) | +3,000 | $57.1K | EDGAR |
| 2012-06-11 | — | Tax (F) | −23,341 | -$233.9K | |
| 2012-06-06 | — | Grant (A) | +60,000 | $606.0K | |
| 2012-05-22 | Seagen Inc. (SGEN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2012-05-14 | — | Tax (F) | −4,999 | -$58.1K | |
| 2011-12-09 | — | Tax (F) | −23,340 | -$405.9K | |
| 2011-06-09 | — | Tax (F) | −18,340 | -$615.2K | |
| 2011-05-24 | Seagen Inc. (SGEN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2011-05-18 | — | Tax (F) | −2,412 | -$92.6K | |
| 2011-05-18 | — | Mixed | −25,863 | -$967.4K |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.